|1.||Ortega, Hector G: 7 articles (12/2015 - 11/2011)|
|2.||Pavord, Ian D: 7 articles (08/2015 - 03/2009)|
|3.||Gleich, Gerald J: 5 articles (05/2014 - 03/2008)|
|4.||Robinson, Douglas S: 4 articles (06/2015 - 01/2003)|
|5.||Ortega, Hector: 4 articles (09/2014 - 08/2012)|
|6.||Nair, Parameswaran: 4 articles (01/2014 - 03/2009)|
|7.||Rothenberg, Marc E: 4 articles (02/2013 - 01/2004)|
|8.||Yancey, Steven W: 3 articles (09/2014 - 05/2014)|
|9.||Keene, Oliver N: 3 articles (09/2014 - 08/2012)|
|10.||Schwartz, Lawrence B: 3 articles (02/2013 - 03/2008)|
|1.||Asthma (Bronchial Asthma)
09/25/2014 - "In patients requiring daily oral glucocorticoid therapy to maintain asthma control, mepolizumab had a significant glucocorticoid-sparing effect, reduced exacerbations, and improved control of asthma symptoms. "
01/01/2013 - "Mepolizumab reduces the risk of exacerbations and improves quality of life in patients with eosinophilic asthma, but no significant improvement in lung function outcomes was observed. "
01/01/2013 - "Mepolizumab was also associated with significantly decreased exacerbation risk than placebo (OR 0.30, 95%CI 0.13 to 0.67, P = 0.004), and with a significant improvement in the scores on the Asthma Quality of Life Questionnaire (AQLQ) (MD 0.26, 95% CI 0.03 to 0.49, P = 0.03) in patients with eosinophilic asthma. "
08/18/2012 - "Mepolizumab is an effective and well tolerated treatment that reduces the risk of asthma exacerbations in patients with severe eosinophilic asthma. "
06/01/2009 - "Mepolizumab may be a promising anti-inflammatory therapy in asthma subgroups with heavy eosinophilic load in which conventional anti-inflammatory therapy is only partially effective."
|2.||Hypereosinophilic Syndrome (Loeffler Endocarditis)
03/20/2008 - "We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome. "
01/01/2008 - "Mepolizumab received orphan drug status for first-line treatment in patients with hypereosinophilic syndrome in the US and the EU in 2004. "
03/20/2008 - "Our study shows that treatment with mepolizumab, an agent designed to target eosinophils, can result in corticosteroid-sparing for patients negative for FIP1L1-PDGFRA who have the hypereosinophilic syndrome. "
02/01/2013 - "Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes."
10/01/2010 - "Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome."
02/01/2013 - "When patients were selected for persistent sputum eosinophilia despite high-dose ICS/OCS, and frequent exacerbations, mepolizumab reduced exacerbations by 50%. "
01/01/2010 - "As assessed by immunofluorescence, a marked reduction of mean oesophageal eosinophilia (p = 0.03) was seen in the mepolizumab group (-54%) compared with the placebo group (-5%) 4 weeks after initiation of treatment. "
08/01/2001 - "In an IL-2--induced eosinophilia model (up to 50% blood eosinophilia), 0.5 mg/kg mepolizumab blocked eosinophilia by >80%. "
06/01/2009 - "Evaluation of the efficacy and safety data on mepolizumab in two studies performed in patients with refractory and corticosteroid-dependent asthma with persistent sputum eosinophilia. "
12/01/2007 - "Further studies are needed to investigate the effect of mepolizumab on exacerbation rates, using protocols specifically tailored to patients with asthma with persistent airway eosinophilia."
09/01/2014 - "Patients with eosinophilic inflammation received significant therapeutic benefit with mepolizumab, and responses differed within clusters. "
01/01/2008 - "In previous clinical studies, including trials in the EU and US, mepolizumab has shown a lack of effect on allergen-induced airway responses and inflammation despite a significant reduction in blood and sputum eosinophil levels.A randomized, double-blind, placebo-controlled, multicentre, phase III study of mepolizumab over 9 months in 85 patients with hypereosinophilic syndrome was completed in 2006. "
12/01/2015 - "In the phase III MENSA trial in patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation despite high-dose inhaled glucocorticoid therapy, mepolizumab significantly reduced the annualized exacerbation rate. "
02/01/2013 - "Mepolizumab can reduce exacerbation rates in the severe asthma cohort who have eosinophilic airway inflammation despite corticosteroid treatment. "
08/18/2012 - "Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk of exacerbations. "
|5.||Churg-Strauss Syndrome (Allergic Angiitis)
10/01/2011 - "The anti-IL-5 antibody mepolizumab (anti-IL-5) induces remission in Churg-Strauss syndrome."
01/01/2008 - "Brigham and Women's Hospital in association with GSK is conducting a phase I/II trial of mepolizumab in patients with Churg-Strauss Syndrome (CSS) in the US. "
01/01/2012 - "Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome."
06/01/2010 - "Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome."
01/01/2010 - "Sustained response to mepolizumab in refractory Churg-Strauss syndrome."
|1.||Interleukin-5 (Interleukin 5)
|5.||Interleukin-6 (Interleukin 6)
|6.||Immunoglobulin G (IgG)
|7.||Adrenal Cortex Hormones (Corticosteroids)
|8.||Interleukin 1 Receptor Antagonist Protein (Anakinra)
|9.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)